Neurological complications associated with left ventricular assist device therapy

References

• Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345(20):1435–1443.
   PubMed Web of Science ®Google Scholar
• Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361(23):2241–2251.
   PubMed Web of Science ®Google Scholar
• Kirklin JK, Pagani FD, Kormos RL, et al. Eighth annual INTERMACS report: special focus on framing the impact of adverse events. J Heart Lung Transplant. 2017;36(10):1080–1086.
   PubMed Web of Science ®Google Scholar
• Harvey L, Holley C, Roy SS, et al. Stroke after left ventricular assist device implantation: outcomes in the continuous-flow era. Ann Thorac Surg. 2015;100(2):535–541.
   PubMed Web of Science ®Google Scholar
• Tsukui H, Abla A, Teuteberg JJ, et al. Cerebrovascular accidents in patients with a ventricular assist device. J Thorac Cardiovasc Surg. 2007;134(1):114–123.
   PubMed Web of Science ®Google Scholar
• Frontera JA, Starling R, Cho SM, et al. Risk factors, mortality, and timing of ischemic and hemorrhagic stroke with left ventricular assist devices. J Heart Lung Transplant. 2017;36(6):673–683.
   PubMed Web of Science ®Google Scholar
• Boyle AJ, Jorde UP, Sun B, et al. Pre-operative risk factors of bleeding and stroke during left ventricular assist device support: an analysis of more than 900 HeartMate II outpatients. J Am Coll Cardiol. 2014;63(9):880–888.
   PubMedGoogle Scholar
• Himmelreich G, Ullmann H, Riess H, et al. Pathophysiologic role of contact activation in bleeding followed by thromboembolic complications after implantation of a ventricular assist device. ASAIO J. 1995;41(3):M790–M794.
   PubMedGoogle Scholar
• Sin DC, Kei HL, Miao X. Surface coatings for ventricular assist devices. Expert Rev Med Devices. 2009;6(1):51–60.
   PubMed Web of Science ®Google Scholar
• Crow S, Chen D, Milano C, et al. Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients. Ann Thorac Surg. 2010;90(4):1263–1269; discussion 1269.
   PubMed Web of Science ®Google Scholar
• Vincent F, Rauch A, Loobuyck V, et al. Arterial pulsatility and circulating von willebrand factor in patients on mechanical circulatory support. J Am Coll Cardiol. 2018;71(19):2106–2118.
   PubMed Web of Science ®Google Scholar
• Edwards AL, Fitzmorris P, Pamboukian SV, et al. Association of pulsatility with gastrointestinal bleeding in a cohort of heartmate II recipients. ASAIO J. 2018;64(4):472–479.
   PubMed Web of Science ®Google Scholar
• Starke RD, Ferraro F, Paschalaki KE, et al. Endothelial von willebrand factor regulates angiogenesis. Blood. 2011;117(3):1071–1080.
   PubMed Web of Science ®Google Scholar
• Shah P, Mehta VM, Cowger JA, et al. D. Diagnosis of hemolysis and device thrombosis with lactate dehydrogenase during left ventricular assist device support. J Heart Lung Transplant. 2014;33(1):102–104.
   PubMed Web of Science ®Google Scholar
• Tran PL, Pietropaolo MG, Valerio L, et al. Hemolysate-mediated platelet aggregation: an additional risk mechanism contributing to thrombosis of continuous flow ventricular assist devices. Perfusion. 2016;31(5):401–408.
   PubMed Web of Science ®Google Scholar
• Bartoli CR, Zhang D, Kang J, et al. Clinical and in vitro evidence that subclinical hemolysis contributes to LVAD thrombosis. Ann Thorac Surg. 2018;105(3):807–814.
   PubMed Web of Science ®Google Scholar
• Studt JD, Kremer Hovinga JA, Antoine G, et al. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood. 2005;105(2):542–544.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Han H, Cruz MA, et al. Haemoglobin blocks von Willebrand factor proteolysis by ADAMTS-13: a mechanism associated with sickle cell disease. Thromb Haemost. 2009;101(6):1070–1077.
   PubMed Web of Science ®Google Scholar
• Majeed F, Kop WJ, Poston RS, et al. Prospective, observational study of antiplatelet and coagulation biomarkers as predictors of thromboembolic events after implantation of ventricular assist devices. Nat Clin Pract Cardiovasc Med. 2009;6(2):147–157.
   PubMedGoogle Scholar
• John R, Lee S. The biological basis of thrombosis and bleeding in patients with ventricular assist devices. J Cardiovasc Transl Res. 2009;2(1):63–70.
   PubMed Web of Science ®Google Scholar
• Pereira NL, Chen D, Kushwaha SS, et al. Discontinuation of antithrombotic therapy for a year or more in patients with continuous-flow left ventricular assist devices. Interact Cardiovasc Thorac Surg. 2010;11(4):503–505.
   PubMed Web of Science ®Google Scholar
• Lietz K, Brown K, Ali SS, et al. The role of cerebral hyperperfusion in postoperative neurologic dysfunction after left ventricular assist device implantation for end-stage heart failure. J Thorac Cardiovasc Surg. 2009;137(4):1012–1019.
   PubMed Web of Science ®Google Scholar
• Bozkurt S. Effect of cerebral flow autoregulation function on cerebral flow rate under continuous flow left ventricular assist device support. Artif Organs. 2018;42(8):800–813.
   PubMed Web of Science ®Google Scholar
• Bellapart J, Chan GS, Tzeng YC, et al. The effect of ventricular assist devices on cerebral autoregulation: a preliminary study. BMC Anesthesiol. 2011;11:4.
   PubMed Web of Science ®Google Scholar
• Morris AA, Pekarek A, Wittersheim K, et al. Gender differences in the risk of stroke during support with continuous-flow left ventricular assist device. J Heart Lung Transplant. 2015;34(12):1570–1577.
   PubMed Web of Science ®Google Scholar
• Bogaev RC, Pamboukian SV, Moore SA, et al. Comparison of outcomes in women versus men using a continuous-flow left ventricular assist device as a bridge to transplantation. J Heart Lung Transplant. 2011;30(5):515–522.
   PubMed Web of Science ®Google Scholar
• Morgan JA, Brewer RJ, Nemeh HW, et al. Stroke while on long-term left ventricular assist device support: incidence, outcome, and predictors. ASAIO J. 2014;60(3):284–289.
   PubMed Web of Science ®Google Scholar
• Mehra MR, Stewart GC, Uber PA. The vexing problem of thrombosis in long-term mechanical circulatory support. J Heart Lung Transplant. 2014;33(1):1–11.
   PubMed Web of Science ®Google Scholar
• John R, Naka Y, Park SJ, et al. Impact of concurrent surgical valve procedures in patients receiving continuous-flow devices. J Thorac Cardiovasc Surg. 2014;147(2):581–589; discussion 589.
   PubMed Web of Science ®Google Scholar
• Rogers JG, Pagani FD, Tatooles AJ, et al. Intrapericardial left ventricular assist device for advanced heart failure. N Engl J Med. 2017;376(5):451–460.
   PubMed Web of Science ®Google Scholar
• Mehra MR, Naka Y, Uriel N, et al. A fully magnetically levitated circulatory pump for advanced heart failure. N Engl J Med. 2017;376(5):440–450.
   PubMed Web of Science ®Google Scholar
• Mehra MR, Goldstein DJ, Uriel N, et al. Two-year outcomes with a magnetically levitated cardiac pump in heart failure. N Engl J Med. 2018;378(15):1386–1395.
   PubMed Web of Science ®Google Scholar
• Gustafsson F, Shaw S, Lavee J, et al. Six-month outcomes after treatment of advanced heart failure with a full magnetically levitated continuous flow left ventricular assist device: report from the ELEVATE registry. Eur Heart J. 2018;39(37):3454–3460.
   PubMed Web of Science ®Google Scholar
• Willey JZ, Gavalas MV, Trinh PN, et al. Outcomes after stroke complicating left ventricular assist device. J Heart Lung Transplant. 2016;35(8):1003–1009.
   PubMed Web of Science ®Google Scholar
• Cho SM, Moazami N, Frontera JA. Stroke and intracranial hemorrhage in heartmate II and heartware left ventricular assist devices: a systematic review. Neurocrit Care. 2017;27(1):17–25.
   PubMed Web of Science ®Google Scholar
• Lalonde SD, Alba AC, Rigobon A, et al. Clinical differences between continuous flow ventricular assist devices: a comparison between heartmate II and heartware HVAD. J Card Surg. 2013;28(5):604–610.
   PubMed Web of Science ®Google Scholar
• Pagani FD, Milano CA, Tatooles AJ, et al. HeartWare HVAD for the treatment of patients with advanced heart failure ineligible for cardiac transplantation: Results of the ENDURANCE destination therapy trial. in. vol 34. J Heart Lung Transplant. 2015;S9.
   Google Scholar
• Stulak JM, Davis ME, Haglund N, et al. Adverse events in contemporary continuous-flow left ventricular assist devices: a multi-institutional comparison shows significant differences. J Thorac Cardiovasc Surg. 2016;151(1):177–189.
   PubMed Web of Science ®Google Scholar
• Backes D, van Den Bergh WM, van Duijn AL, et al. Cerebrovascular complications of left ventricular assist devices. Eur J Cardiothorac Surg. 2012;42(4):612–620.
   PubMed Web of Science ®Google Scholar
• Harvey L, Holley CT, John R. Gastrointestinal bleed after left ventricular assist device implantation: incidence, management, and prevention. Ann Cardiothorac Surg. 2014;3(5):475–479.
   PubMedGoogle Scholar
• Bashir J, Legare JF, Freed DH, et al. Multicentre Canadian experience with the heartware ventricular assist device: concerns about adverse neurological outcomes. Can J Cardiol. 2014;30(12):1662–1667.
   PubMed Web of Science ®Google Scholar
• Acharya D, Loyaga-Rendon R, Morgan CJ, et al. INTERMACS analysis of stroke during support with continuous-flow left ventricular assist devices: risk factors and outcomes. JACC Heart Fail. 2017;5(10):703–711.
   PubMed Web of Science ®Google Scholar
• Uriel N, Colombo PC, Cleveland JC, et al. Hemocompatibility-related outcomes in the MOMENTUM 3 trial at 6 months: a randomized controlled study of a fully magnetically levitated pump in advanced heart failure. Circulation. 2017;135(21):2003–2012.
   PubMed Web of Science ®Google Scholar
• Netuka I, Sood P, Pya Y, et al. Fully magnetically levitated left ventricular assist system for treating advanced HF: a multicenter study. J Am Coll Cardiol. 2015;66(23):2579–2589.
   PubMed Web of Science ®Google Scholar
• Netuka I, Kvasnička T, Kvasnička J, et al. Evaluation of von Willebrand factor with a fully magnetically levitated centrifugal continuous-flow left ventricular assist device in advanced heart failure. J Heart Lung Transplant. 2016;35(7):860–867.
   PubMed Web of Science ®Google Scholar
• Willey JZ, Demmer RT, Takayama H, et al. Cerebrovascular disease in the era of left ventricular assist devices with continuous flow: risk factors, diagnosis, and treatment. J Heart Lung Transplant. 2014;33(9):878–887.
   PubMed Web of Science ®Google Scholar
• Aggarwal A, Gupta A, Kumar S, et al. Are blood stream infections associated with an increased risk of hemorrhagic stroke in patients with a left ventricular assist device? ASAIO J. 2012;58(5):509–513.
   PubMed Web of Science ®Google Scholar
• Yuan N, Arnaoutakis GJ, George TJ, et al. The spectrum of complications following left ventricular assist device placement. J Card Surg. 2012;27(5):630–638.
   PubMed Web of Science ®Google Scholar
• Elkind MS. Inflammatory mechanisms of stroke. Stroke. 2010;41(10 Suppl):S3–S8.
   PubMed Web of Science ®Google Scholar
• Maltais S, Kilic A, Nathan S, et al. PREVENtion of heartmate II pump thrombosis through clinical management: the PREVENT multi-center study. J Heart Lung Transplant. 2017;36(1):1–12.
   PubMed Web of Science ®Google Scholar
• Teuteberg JJ, Slaughter MS, Rogers JG, et al. The HVAD left ventricular assist device: risk factors for neurological events and risk mitigation strategies. JACC Heart Fail. 2015;3(10):818–828.
   PubMed Web of Science ®Google Scholar
• Kato TS, Schulze PC, Yang J, et al. Pre-operative and post-operative risk factors associated with neurologic complications in patients with advanced heart failure supported by a left ventricular assist device. J Heart Lung Transplant. 2012;31(1):1–8.
   PubMed Web of Science ®Google Scholar
• Smith LA, Yarboro LT, Kennedy JL. Left ventricular assist device implantation strategies and outcomes. J Thorac Dis. 2015;7(12):2088–2096.
   PubMed Web of Science ®Google Scholar
• Bhimaraj A, Uribe C, Suarez EE. Physiological impact of continuous flow on end-organ function: clinical implications in the current era of left ventricular assist devices. Methodist Debakey Cardiovasc J. 2015;11(1):12–17.
   PubMedGoogle Scholar
• Cornwell WK, Tarumi T, Aengevaeren VL, et al. Effect of pulsatile and nonpulsatile flow on cerebral perfusion in patients with left ventricular assist devices. J Heart Lung Transplant. 2014;33(12):1295–1303.
   PubMed Web of Science ®Google Scholar
• Jennings DL, Jacob M, Chopra A, et al. Safety of anticoagulation reversal in patients supported with continuous-flow left ventricular assist devices. ASAIO J. 2014;60(4):381–384.
   PubMed Web of Science ®Google Scholar
• Kamdar F, Eckman P, John R. Safety of discontinuation of anti-coagulation in patients with continuous-flow left ventricular assist devices. J Heart Lung Transplant. 2014;33(3):316–318.
   PubMed Web of Science ®Google Scholar
• Wilson TJ, Stetler WR, Al-Holou WN, et al. Management of intracranial hemorrhage in patients with left ventricular assist devices. J Neurosurg. 2013;118(5):1063–1068.
   PubMed Web of Science ®Google Scholar
• Patlolla V, Mogulla V, DeNofrio D, et al. Outcomes in patients with symptomatic cerebrovascular disease undergoing heart transplantation. J Am Coll Cardiol. 2011;58(10):1036–1041.
   PubMed Web of Science ®Google Scholar
• Petrucci RJ, Wright S, Naka Y, et al. Neurocognitive assessments in advanced heart failure patients receiving continuous-flow left ventricular assist devices. J Heart Lung Transplant. 2009;28(6):542–549.
   PubMed Web of Science ®Google Scholar
• Stroke Facts. Published 2017. [cited 2018 Feb 1]. Available from: www.cdc.gov/stroke/facts.htm
   Google Scholar